|
Gene: ROBO3 |
Gene summary for ROBO3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ROBO3 | Gene ID | 64221 |
Gene name | roundabout guidance receptor 3 | |
Gene Alias | HGPPS | |
Cytomap | 11q24.2 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q96MS0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64221 | ROBO3 | P2T-E | Human | Esophagus | ESCC | 3.79e-20 | 3.07e-01 | 0.1177 |
64221 | ROBO3 | P4T-E | Human | Esophagus | ESCC | 6.42e-12 | 1.41e-01 | 0.1323 |
64221 | ROBO3 | P5T-E | Human | Esophagus | ESCC | 4.09e-02 | -1.81e-02 | 0.1327 |
64221 | ROBO3 | P8T-E | Human | Esophagus | ESCC | 3.69e-04 | 3.16e-02 | 0.0889 |
64221 | ROBO3 | P10T-E | Human | Esophagus | ESCC | 5.10e-12 | 2.20e-01 | 0.116 |
64221 | ROBO3 | P11T-E | Human | Esophagus | ESCC | 1.69e-04 | 1.34e-01 | 0.1426 |
64221 | ROBO3 | P16T-E | Human | Esophagus | ESCC | 2.38e-23 | 4.41e-01 | 0.1153 |
64221 | ROBO3 | P19T-E | Human | Esophagus | ESCC | 3.39e-02 | 2.57e-01 | 0.1662 |
64221 | ROBO3 | P21T-E | Human | Esophagus | ESCC | 2.09e-10 | 7.79e-02 | 0.1617 |
64221 | ROBO3 | P22T-E | Human | Esophagus | ESCC | 3.29e-07 | 1.34e-03 | 0.1236 |
64221 | ROBO3 | P24T-E | Human | Esophagus | ESCC | 7.45e-05 | 1.44e-02 | 0.1287 |
64221 | ROBO3 | P26T-E | Human | Esophagus | ESCC | 1.43e-35 | 5.21e-01 | 0.1276 |
64221 | ROBO3 | P27T-E | Human | Esophagus | ESCC | 1.09e-07 | 1.07e-01 | 0.1055 |
64221 | ROBO3 | P28T-E | Human | Esophagus | ESCC | 9.69e-03 | -8.19e-03 | 0.1149 |
64221 | ROBO3 | P30T-E | Human | Esophagus | ESCC | 1.10e-02 | 8.71e-02 | 0.137 |
64221 | ROBO3 | P31T-E | Human | Esophagus | ESCC | 4.46e-12 | 2.96e-01 | 0.1251 |
64221 | ROBO3 | P37T-E | Human | Esophagus | ESCC | 1.36e-15 | 2.42e-01 | 0.1371 |
64221 | ROBO3 | P44T-E | Human | Esophagus | ESCC | 3.38e-02 | 1.47e-02 | 0.1096 |
64221 | ROBO3 | P47T-E | Human | Esophagus | ESCC | 3.97e-04 | -1.25e-02 | 0.1067 |
64221 | ROBO3 | P49T-E | Human | Esophagus | ESCC | 4.73e-14 | 1.13e+00 | 0.1768 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
GO:006156423 | Thyroid | ATC | axon development | 220/6293 | 467/18723 | 6.85e-10 | 1.80e-08 | 220 |
GO:000740919 | Thyroid | ATC | axonogenesis | 197/6293 | 418/18723 | 5.09e-09 | 1.13e-07 | 197 |
GO:00074113 | Thyroid | ATC | axon guidance | 96/6293 | 227/18723 | 3.74e-03 | 1.63e-02 | 96 |
GO:00974853 | Thyroid | ATC | neuron projection guidance | 96/6293 | 228/18723 | 4.36e-03 | 1.81e-02 | 96 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0436016 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0436017 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ROBO3 | SNV | Missense_Mutation | novel | c.3101G>A | p.Gly1034Glu | p.G1034E | Q96MS0 | protein_coding | deleterious(0.01) | benign(0.005) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROBO3 | SNV | Missense_Mutation | rs554513575 | c.3893N>A | p.Arg1298His | p.R1298H | Q96MS0 | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ROBO3 | SNV | Missense_Mutation | novel | c.1707N>T | p.Lys569Asn | p.K569N | Q96MS0 | protein_coding | deleterious(0) | possibly_damaging(0.827) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROBO3 | SNV | Missense_Mutation | novel | c.3359N>T | p.Arg1120Ile | p.R1120I | Q96MS0 | protein_coding | deleterious(0) | possibly_damaging(0.548) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROBO3 | SNV | Missense_Mutation | rs369554878 | c.1292N>A | p.Gly431Asp | p.G431D | Q96MS0 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-EY-A1GF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROBO3 | SNV | Missense_Mutation | novel | c.1706N>T | p.Lys569Met | p.K569M | Q96MS0 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ROBO3 | SNV | Missense_Mutation | novel | c.3460N>T | p.Ala1154Ser | p.A1154S | Q96MS0 | protein_coding | deleterious(0.04) | possibly_damaging(0.907) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ROBO3 | SNV | Missense_Mutation | rs772718098 | c.3911C>T | p.Ala1304Val | p.A1304V | Q96MS0 | protein_coding | tolerated_low_confidence(0.38) | benign(0) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROBO3 | SNV | Missense_Mutation | rs529624379 | c.1525G>A | p.Ala509Thr | p.A509T | Q96MS0 | protein_coding | tolerated(1) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ROBO3 | SNV | Missense_Mutation | novel | c.3281T>C | p.Leu1094Pro | p.L1094P | Q96MS0 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |